After US biotech Biogen (Nasdaq: BIIB) presented further analysis from two Phase III trials of its Alzheimer’s candidate, aducanumab, the company’s stock price closed up more than 3% on Thursday.
It was a similar story in Friday’s Tokyo trading for Biogen’s partner, Eisai (TYO: 4523), with the results presented at the Clinical Trials on Alzheimer’s Disease conference in San Diego suggesting that aducanumab worked at higher doses in a percentage of the study population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze